{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:01:18Z","timestamp":1784847678380,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the clinically significant prostate cancer detection rate (csPCaDR) and pathological characteristics of magnetic resonance imaging (MRI) visible (MRIv) and MRI invisible (MRIi) cancers among men undergoing surveillance after ablative focal therapy (AFT) for intermediate\u2010risk PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A total of 305 five men enrolled in an Institutional Review Board\u2010approved primary partial gland cryoablation (PPGCA) outcomes registry meeting the following inclusion criteria: an MRI region of interest (ROI) Prostate Imaging\u2010Reporting and Data System 2\u20135 concordant with unilateral intermediate\u2010risk disease (Gleason Grade Group [GGG] 2 or 3 disease), no gross extraprostatic extension on MRI, no GGG \u22652 contralateral to the ROI, and at least 6\u2009months of follow\u2010up. Protocol MRI was performed at 6, 24, 42 and 60\u2009months. Biopsy indications evolved over time. Any Gleason pattern 4 (GP4) represented a clinically significant PCa recurrence (csPCaR). Pathological disease characteristics, csPCaDR, and salvage treatments were compared for MRIv and MRIi disease. Baseline and post\u2010treatment characteristics were compared between MRIv and MRIi csPCaR. Ordinal and binary measures were compared with Mann\u2013Whitney rank\u2010sum test. Categorical testing for differences was performed with chi\u2010square testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 665 post\u2010treatment MRIs, 87 (13.1%) and 578 (86.9%) were positive (+ve) and negative (\u2212ve) for csPCaR, respectively. Biopsies were taken in 62 of the 87 +ve MRIs and 179 of the 578 \u2212ve MRIs, with a csPCaDR of 43.5% and 10.6% for +ve and \u2212ve MRI, respectively. Of the 46 csPCaRs, 28 (61%) and 18 (39%) were associated with +ve and \u2212ve MRI, respectively. The median linear length of GP4 for MRIv and MRIi csPCaR was 2.6 and 0.6\u2009mm, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.08). Four (14%) and eight (44%) MRIv and MRIi csPCaRs were managed with continued active surveillance (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The cost and morbidity of surveillance following PPGCA can be safely reduced by avoiding biopsy in most cases with \u2013ve MRI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16772","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:34:43Z","timestamp":1747208083000},"page":"447-451","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Routine prostate biopsies not needed after cryotherapy if surveillance\n                    <scp>MRI<\/scp>\n                    is normal"],"prefix":"10.1111","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-835X","authenticated-orcid":false,"given":"Herbert","family":"Lepor","sequence":"first","affiliation":[{"name":"Department of Urology NYU Grossman School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-3333","authenticated-orcid":false,"given":"Jesse","family":"Persily","sequence":"additional","affiliation":[{"name":"Department of Urology NYU Grossman School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Parry","sequence":"additional","affiliation":[{"name":"Department of Urology NYU Grossman School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-3950","authenticated-orcid":false,"given":"Eli","family":"Rapoport","sequence":"additional","affiliation":[{"name":"Department of Urology NYU Grossman School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majlinda","family":"Tafa","sequence":"additional","affiliation":[{"name":"Department of Urology NYU Grossman School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-0947","authenticated-orcid":false,"given":"James S.","family":"Wysock","sequence":"additional","affiliation":[{"name":"Department of Urology NYU Grossman School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.10.014"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00685-z"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-014-1475-2"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.05.018"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0244-0"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003569"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.04.001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.035"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004069"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.23180"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123074"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072605"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.031"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001406"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209454"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.11.017"},{"key":"e_1_2_8_20_1","first-page":"203","article-title":"Focal therapy: a new paradigm for the treatment of prostate cancer","volume":"11","author":"Tareen B","year":"2009","journal-title":"Rev Urol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.021"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.11.008"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:55:03Z","timestamp":1761724503000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/bju.16772"],"URL":"https:\/\/doi.org\/10.1111\/bju.16772","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2025-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}